Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
1.
Heart ; 107(1): 61-66, 2021 01.
Article in English | MEDLINE | ID: mdl-32669396

ABSTRACT

OBJECTIVES: Women with Turner syndrome (TS) are frequently counselled against pregnancy due to lack of data and unclear aortic dissection risk. However, with advances in fertility therapy, more women with TS are contemplating pregnancy. This study compared rates of adverse cardiovascular (CV) outcomes among: (1) pregnant and non-pregnant women with TS and (2) pregnant women with TS with/without structural heart disease. METHODS: Retrospective analysis of pregnant and age-matched non-pregnant controls with TS (2005-2017) across 10 CV centres was done. Data were collected at initial evaluation in pregnancy and outcomes were assessed to 6 months postpartum. Adverse CV events were defined as CV death, aortic dissection/rupture and/or aortic intervention. Non-pregnant age-matched controls were followed over the same time period. RESULTS: Sixty-eight pregnancies were included (60 women, mean age 33 years, 48% primigravid, 49% fertility therapy, 80% structurally normal heart, 25% XO karyotype). Based on American Society of Reproductive Medicine criteria, 10 pregnancies occurred in women stratified to high-risk category. There were no CV events in the pregnant women or in the non-pregnant women with TS. Obstetric events complicated 12 (18%) pregnancies with 9 (13%) attributed to hypertensive disorder of pregnancy. Fetal events included small for gestational age neonates (18%), preterm delivery (15%) and fetal death (3%). CONCLUSIONS: This study helps to refine the approach to pregnancy in women with TS. Among women with TS without structural heart disease, pregnancy does not impose an increased risk of CV outcomes. Among women with TS with structural heart disease, the risk of pregnancy is not as prohibitive as previously described but does require ongoing evaluation.


Subject(s)
Pregnancy Complications , Pregnancy Outcome , Turner Syndrome , Adult , Female , Humans , Infant, Newborn , Pregnancy , Pregnancy Complications/therapy , Retrospective Studies , Turner Syndrome/therapy
2.
Int J Cardiol ; 322: 149-157, 2021 01 01.
Article in English | MEDLINE | ID: mdl-32798623

ABSTRACT

BACKGROUND: Heart failure (HF) is the leading cause of death in adult patients with congenital heart disease (ACHD). No risk prediction model exists for HF hospitalization (HFH) for ACHD patients. We aimed to develop a clinically relevant one-year risk prediction system to identify ACHD patients at high risk for HFH. METHODS: Data source was the Quebec CHD Database. A retrospective cohort including all ACHD patients aged 18-64 (1995-2010) was constructed for assessing the cumulative risk of HFH adjusting for competing risk of death. To identify one-year predictors of incident HFH, multivariable logistic regressions were employed to a nested case-control sample of all ACHD patients aged 18-64 in 2009. The final model was used to create a risk score system based on adjusted odds ratios. RESULTS: The cohort included 29,991 ACHD patients followed for 648,457 person-years. The cumulative HFH risk by age 65 was 12.58%. The case-control sample comprised 26,420 subjects, of whom 189 had HFHs. Significant one-year predictors were age ≥ 50, male sex, CHD lesion severity, recent 12-month HFH history, pulmonary arterial hypertension, chronic kidney disease, coronary artery disease, systemic arterial hypertension, and diabetes mellitus. The created risk score ranged from 0 to 19. The corresponding HFH risk rose rapidly beyond a score of 8. The risk scoring system demonstrated excellent prediction performance. CONCLUSIONS: One eighth of ACHD population experienced HFH before age 65. Age, sex, CHD lesion severity, recent 12-month HFH history, and comorbidities constructed a risk prediction model that successfully identified patients at high risk for HFH.


Subject(s)
Heart Defects, Congenital , Heart Failure , Adolescent , Adult , Aged , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/epidemiology , Heart Failure/diagnosis , Heart Failure/epidemiology , Hospitalization , Humans , Male , Middle Aged , Quebec , Retrospective Studies , Young Adult
4.
Can J Cardiol ; 35(12): 1686-1697, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31635950

ABSTRACT

Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have several advantages over VKAs that render them an attractive option for adults with congenital heart disease (CHD). Efficacy and safety data specific to the adult CHD population are emerging. Herein, we synthesize the growing literature regarding NOACs in adults with CHD and attempt to identify subgroups for which it appears reasonable to extrapolate data from populations without CHD. Small observational studies suggest that NOACs are safe and effective in selected adults with CHD. NOACs are contraindicated in patients with a mechanical valve, in those with mitral or tricuspid valve stenosis with enlarged and diseased atria, with or without a mitral or tricuspid bioprosthesis, and after recent cardiac surgery (< 3 months). There is currently insufficient evidence to recommend NOACs in patients with a Fontan circulation or cyanotic CHD. Growing literature supports the use of NOACs in patients without CHD who have various forms of valvular heart disease. Therefore, when an indication for oral anticoagulation is established, it appears reasonable to consider a NOAC instead of a VKA in adults with CHD lesions analogous to isolated mitral regurgitation, tricuspid regurgitation, or aortic regurgitation or stenosis. The NOAC agent selected and the prescribed dose should be tailored according to bleeding risk, body weight, renal function, and comedications, especially antiepileptic drugs. The decision to initiate a NOAC should be shared between the patient and care provider. Large-scale research studies are required to further assess safety and efficacy in selected patient subgroups.


Subject(s)
Anticoagulants/therapeutic use , Antithrombins/administration & dosage , Atrial Fibrillation/drug therapy , Heart Defects, Congenital/complications , Heart Valve Diseases/drug therapy , Administration, Oral , Adult , Age Factors , Anticoagulants/pharmacology , Atrial Fibrillation/etiology , Atrial Fibrillation/mortality , Blood Coagulation/drug effects , Dabigatran/administration & dosage , Dabigatran/adverse effects , Female , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/surgery , Heart Valve Diseases/etiology , Heart Valve Diseases/mortality , Humans , Male , Prognosis , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Pyridines/administration & dosage , Pyridines/adverse effects , Pyridones/administration & dosage , Pyridones/adverse effects , Risk Assessment , Severity of Illness Index , Sex Factors , Stroke/prevention & control , Survival Analysis , Thiazoles/administration & dosage , Thiazoles/adverse effects , Vitamin K/antagonists & inhibitors
5.
Int J Cardiol ; 272: 77-83, 2018 12 01.
Article in English | MEDLINE | ID: mdl-30017529

ABSTRACT

The population of adults with congenital heart disease (ACHD) is increasing constantly due to medical, surgical and interventional successes and the input from advanced cardiovascular imaging. ACHD patients are at continuing risk of residua and sequelae related to their CHD contributing to significant morbidity and mortality. Consequently, lifelong expert surveillance is recommended for most patients. Healthcare providers are still working out how best to achieve this objective, how to train enough experts to provide high quality care, and how to organize the delivery of care. Echocardiography is crucial to clinical surveillance providing a comprehensive assessment of cardiac morphology, physiology, pathophysiology, and function. Thus it contributes significantly to the overall clinical management of ACHD patients. The International Society for Adult Congenital Heart Disease (ISACHD; www.isachd.org) is the leading organization of professionals worldwide dedicated to the pursuit of excellence in the care of ACHD patients. Recognizing the critical role of imaging in the diagnosis and management of ACHD, ISACHD established a task force to provide guidance on echocardiographic studies and reporting. The rationale is that standardization of echocardiographic imaging and reporting carries the potential to improve the overall quality of these exams around the world and facilitate collaborative multicenter research. The standardized ACHD protocols provided by the ISACHD task force (found in the appendices) include specific recommendations for data acquisition and reporting for each of the major adult congenital heart lesions. These protocols give a comprehensive and structured approach in the evaluation of ACHD patients and help to ensure excellent patient care.


Subject(s)
Consensus , Echocardiography/standards , Heart Defects, Congenital/diagnostic imaging , Internationality , Societies, Medical/standards , Adult , Advisory Committees/standards , Heart Defects, Congenital/therapy , Humans
6.
Genet Med ; 19(4): 386-395, 2017 04.
Article in English | MEDLINE | ID: mdl-27632686

ABSTRACT

PURPOSE: Thoracic aortic aneurysm and dissection (TAAD) is typically inherited in an autosomal dominant manner, but rare X-linked families have been described. So far, the only known X-linked gene is FLNA, which is associated with the periventricular nodular heterotopia type of Ehlers-Danlos syndrome. However, mutations in this gene explain only a small number of X-linked TAAD families. METHODS: We performed targeted resequencing of 368 candidate genes in a cohort of 11 molecularly unexplained Marfan probands. Subsequently, Sanger sequencing of BGN in 360 male and 155 female molecularly unexplained TAAD probands was performed. RESULTS: We found five individuals with loss-of-function mutations in BGN encoding the small leucine-rich proteoglycan biglycan. The clinical phenotype is characterized by early-onset aortic aneurysm and dissection. Other recurrent findings include hypertelorism, pectus deformity, joint hypermobility, contractures, and mild skeletal dysplasia. Fluorescent staining revealed an increase in TGF-ß signaling, evidenced by an increase in nuclear pSMAD2 in the aortic wall. Our results are in line with those of prior reports demonstrating that Bgn-deficient male BALB/cA mice die from aortic rupture. CONCLUSION: In conclusion, BGN gene defects in humans cause an X-linked syndromic form of severe TAAD that is associated with preservation of elastic fibers and increased TGF-ß signaling.Genet Med 19 4, 386-395.


Subject(s)
Aortic Aneurysm, Thoracic/genetics , Aortic Dissection/genetics , Biglycan/genetics , Mutation , Aortic Dissection/metabolism , Aortic Aneurysm, Thoracic/metabolism , Biglycan/metabolism , Cells, Cultured , Female , Genes, X-Linked , Genetic Predisposition to Disease , Humans , Male , Pedigree , Sequence Analysis, DNA/methods , Signal Transduction , Transforming Growth Factor beta/metabolism
8.
Can J Cardiol ; 31(1): 84-7, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25547555

ABSTRACT

Takotsubo cardiomyopathy has become a well recognized mimicker of acute coronary syndrome. Patients generally do well, although a minority can develop life-threatening complications. We present a case of 1 such patient in a branched self-assessment format designed to challenge the reader's clinical management skills.


Subject(s)
Disease Management , Echocardiography/methods , Intra-Aortic Balloon Pumping/methods , Magnetic Resonance Imaging, Cine/methods , Resuscitation/methods , Shock, Cardiogenic/etiology , Takotsubo Cardiomyopathy/complications , Aged , Coronary Angiography , Diagnosis, Differential , Electrocardiography , Follow-Up Studies , Humans , Male , Shock, Cardiogenic/therapy , Takotsubo Cardiomyopathy/diagnosis , Takotsubo Cardiomyopathy/therapy
11.
Vasc Med ; 17(5): 326-9, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22946110

ABSTRACT

Mutations of the ACTA2 gene, which encodes the smooth muscle cell-specific isoform of α-actin protein, have recently been found to be among the most common genetic abnormalities observed in patients with familial thoracic aortic aneurysms/dissection (TAAD). Other reported vascular manifestations caused by these mutations include premature coronary artery disease and stroke. We report a young adult who presented with an acute brachial artery occlusion and was subsequently found to have aortopathy and an ACTA2 mutation. This expands the spectrum of vascular disease associated with ACTA2 mutation to include acute limb ischemia.


Subject(s)
Actins/genetics , Aortic Aneurysm, Thoracic/genetics , Arterial Occlusive Diseases/genetics , Brachial Artery , Ischemia/genetics , Mutation , Thrombosis/genetics , Adolescent , Anticoagulants/therapeutic use , Aortic Aneurysm, Thoracic/diagnosis , Aortic Aneurysm, Thoracic/therapy , Aortography/methods , Arterial Occlusive Diseases/diagnosis , Arterial Occlusive Diseases/therapy , Biopsy , Brachial Artery/diagnostic imaging , Brachial Artery/surgery , Constriction, Pathologic , DNA Mutational Analysis , Embolectomy , Female , Genetic Predisposition to Disease , Humans , Ischemia/diagnosis , Ischemia/therapy , Phenotype , Thrombosis/diagnosis , Thrombosis/therapy , Tomography, X-Ray Computed , Treatment Outcome
12.
Int J Cardiol ; 157(1): 70-4, 2012 May 17.
Article in English | MEDLINE | ID: mdl-21190745

ABSTRACT

BACKGROUND: There are more adults than children with congenital heart disease. Of over 96,000 ACHD patients in Canada, approximately 50% require ongoing expert care. In spite of published recommendations, data on the quality of care for ACHD patients are lacking. METHODS: Survey methodology targeted all Canadian Adult Congenital Heart (CACH) network affiliated ACHD centers. Clinics were asked to prospectively collect outpatient and procedural volumes for 2007. In 2008, centers were surveyed regarding infrastructure, staffing, patient volumes and waiting times. RESULTS: All 15 CACH network registered centers responded. The total number of patients followed in ACHD clinics was 21,879 (median per clinic=1132 (IQR: 585, 1816)). Of the total 80 adult and pediatric cardiologists affiliated to an ACHD clinic, only 27% had received formal ACHD training. Waiting times for non-urgent consultations were 4 ± 2 months, and 4 ± 3 months for percutaneous and surgical procedures. These were beyond Canadian recommended targets at 11 sites (73%) for non-urgent consultations, at 8 sites (53%) for percutaneous interventions and 13 sites (87%) for surgery. CONCLUSIONS: Of a minimum number of 96,000 ACHD patients in Canada, only 21,879 were being regularly followed in 2007. At most sites waiting times for ACHD services were beyond Canadian recommended targets. In spite of universal health care access, published guidelines for ACHD patient structure and process measures of health care quality are not being met.


Subject(s)
Heart Defects, Congenital/epidemiology , Heart Defects, Congenital/therapy , Process Assessment, Health Care/standards , Quality of Health Care/standards , Canada/epidemiology , Data Collection/methods , Follow-Up Studies , Humans , Prospective Studies , Waiting Lists
15.
Eur J Echocardiogr ; 11(2): 198-201, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19919957

ABSTRACT

Mitral annular calcification (MAC) has been considered a risk factor for thrombo-embolic disease. Superimposed thrombus formation on MAC has not been well described as a possible underlying mechanism for this association. We report three patients with mobile left ventricular (LV) thrombus arising from the LV aspect of severe calcified mitral annulus in the setting of normal LV function, mitral valve function, and sinus rhythm.


Subject(s)
Calcinosis/etiology , Heart Ventricles/pathology , Mitral Valve/pathology , Thrombosis/etiology , Ventricular Dysfunction/etiology , Aged , Calcinosis/diagnostic imaging , Calcinosis/pathology , Chest Pain , Disease Progression , Echocardiography , Echocardiography, Transesophageal , Female , Heart Ventricles/diagnostic imaging , Heart Ventricles/surgery , Humans , Male , Middle Aged , Mitral Valve/diagnostic imaging , Mitral Valve/surgery , Risk Factors , Thrombosis/diagnostic imaging , Thrombosis/surgery , Ventricular Dysfunction/diagnostic imaging , Ventricular Dysfunction/surgery
16.
J Am Soc Echocardiogr ; 21(4): 342-6, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17904816

ABSTRACT

BACKGROUND: Many patients with repaired tetralogy of Fallot (TOF) have clinically important pulmonary regurgitation that can eventually lead to right ventricular (RV) dilatation and dysfunction and associated morbidity and mortality. Unfortunately, standard echocardiographic techniques to evaluate RV size and function can be inaccurate. Newer Doppler modalities such as Doppler tissue imaging (DTI) can detect subtle changes in myocardial velocities and may better identify subclinical RV dysfunction in these patients. METHODS: A total of 25 patients with repaired TOF prospectively underwent complete echocardiographic assessment (including DTI) of the RV and cardiopulmonary stress testing to evaluate exercise capacity. Echocardiographic variables were compared with age- and sex-matched control subjects. RESULTS: Patients with repaired TOF had significantly lower RV DTI indices compared with control subjects. In patients with repaired TOF, RV peak systolic velocity had a significant correlation with maximal oxygen consumption during exercise (r = 0.80, P < .001) and was the only independent predictor of maximal oxygen consumption on multivariate analysis (r = 0.80, P < .001). CONCLUSION: DTI identifies abnormalities of RV systolic and diastolic function in patients with repaired TOF. Importantly, RV systolic velocity is predictive of exercise capacity in these patients.


Subject(s)
Echocardiography, Doppler/methods , Exercise Test , Oxygen Consumption , Tetralogy of Fallot/diagnostic imaging , Tetralogy of Fallot/surgery , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve/diagnostic imaging , Ventricular Dysfunction, Right/diagnostic imaging , Adult , Female , Humans , Male , Reproducibility of Results , Sensitivity and Specificity , Tetralogy of Fallot/physiopathology , Treatment Outcome , Tricuspid Valve/physiopathology , Tricuspid Valve Insufficiency/physiopathology , Ventricular Dysfunction, Right/physiopathology
17.
Can J Cardiol ; 23(6): 475-7, 2007 May 01.
Article in English | MEDLINE | ID: mdl-17487293

ABSTRACT

Chronic excess alcohol use is a well-established cause of dilated cardiomyopathy. The clinical features are variable because patients may be asymptomatic despite there being evidence of severe left ventricular dysfunction. Although the mechanism of alcohol-induced cardiomyopathy is not clearly understood, abstinence from alcohol has been associated with improvement in left ventricular function. Conversely, patients with ongoing alcohol abuse and dilated cardiomyopathy have a poor prognosis, with progressive biventricular failure and, ultimately, death. A case of rapid reversal of alcohol-induced cardiomyopathy with abstinence is reviewed. The present case highlights the acute toxic nature of alcohol and the potential for rapid functional recovery.


Subject(s)
Cardiomyopathy, Alcoholic/diagnosis , Cardiomyopathy, Alcoholic/therapy , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiomyopathy, Alcoholic/physiopathology , Diagnosis, Differential , Diuretics/therapeutic use , Electrocardiography , Emergency Treatment , Female , Humans , Middle Aged , Ventricular Dysfunction, Left/physiopathology
19.
Cardiovasc Pathol ; 15(6): 352-3, 2006.
Article in English | MEDLINE | ID: mdl-17113014

ABSTRACT

An 82-year-old female patient with a history of deep vein thrombosis presented with progressive dyspnea. Echocardiogram demonstrated significant pulmonary hypertension and patent ductus arteriosus (PDA). There was considerable debate regarding the role of PDA in the patient's pulmonary hypertension. The patient died of heart failure a few months later. Autopsy demonstrated extensive chronic pulmonary thromboembolic disease. Pulmonary thromboemboli continue to be a diagnostic challenge despite modern diagnostic modalities. Autopsy continues to play a role in investigating unexplained clinical findings and in determining cause of death.


Subject(s)
Ductus Arteriosus, Patent/pathology , Hypertension, Pulmonary/pathology , Aged, 80 and over , Anticoagulants/therapeutic use , Ductus Arteriosus, Patent/complications , Dyspnea/etiology , Dyspnea/pathology , Echocardiography , Fatal Outcome , Female , Heart Failure/etiology , Heart Failure/pathology , Humans , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/therapy , Oxygen Inhalation Therapy , Pulmonary Embolism/complications , Pulmonary Embolism/pathology , Pulmonary Embolism/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...